BMS_986171



NAME OF DRUG : BMS_986171

ALSO KNOWN AS : pegbelfermin

LABORATORY : Bristol-MyersSquibb

STATUS AND ADVANCEMENT

Type of drug : PEG-FGF21

Clinical trials advancement : Analysing Results Phase 2a

Estimated time to market : 112 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON BMS_986171

SOME PUBLICATIONS RELATED WITH BMS_986171

December 2018 : Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH BMS_986171


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE